Stephens raises Zscaler stock price target on strong results

Stephens raised its Zscaler (ZS) price target to $225 from $200 (Overweight) after strong Q4 fiscal 2026 results, including ARR up 25% YoY to $3,771M and a 77% gross margin. The analyst cited accelerating organic net new ARR, positive early traction in Security for AI, and a slightly higher fiscal 2027 ARR growth outlook, while viewing guidance as conservative with upside. Multiple peers also lifted targets (e.g., Needham to $215, Scotiabank to $200), and although Zscaler cut 3% of the workforce and is managing a sales force transition, the overall setup for fiscal 2027 appears more positive.

Analysis

The actionable signal is not the target raise itself; it is the market’s willingness to pay up once execution-risk discounts fade. For ZS, that means the stock can re-rate quickly if investors start underwriting a higher-quality ARR stream rather than treating it as a noisy consumption story. The beneficiaries are the pure-play cyber names with cleaner growth/margin conversion; the losers are slower-growing security vendors whose multiple support depends on bundling or cross-sell rather than standalone demand.

Competitive dynamics matter here: if ZS is truly seeing better sales productivity, it pressures peers to defend share with discounting or heavier channel spend. That would be most painful for companies already using price as a retention tool, while leaving best-in-class growth names relatively insulated. The second-order effect is a widening valuation spread inside cyber: names with stable gross margins and reaccelerating net new ARR can keep commanding premium revenue multiples even if the broader software tape is choppy.

The main risk is that this is a rate-sensitive multiple story masquerading as a fundamental one. A strong macro print can lift enterprise demand expectations, but it can also push yields higher and compress long-duration software valuations over the next few weeks. The 1-3 month catalyst path is next-quarter bookings, cRPO, and guidance consistency; the thesis is falsified if ARR growth stalls, sales transition frictions reappear, or management has to qualify the AI/security pipeline as non-monetizing narrative. Over 6-18 months, sustained margin discipline would matter more than one clean quarter, because that is what turns “good growth” into durable FCF compounding.

Key Decisions for Investors

• Add ZS on pullbacks over the next 1-3 weeks; base case is a modest 8-12% re-rating if FY27 ARR guidance proves conservative, but cut if the stock fails to hold post-upgrade support and yields continue higher.
• Run a sector-neutral long ZS / short CIBR pair for 1-3 months to isolate execution quality versus the cybersecurity basket; this captures relative multiple expansion if ZS keeps accelerating while the ETF remains range-bound.
• If you want lower-convexity exposure, use a 3-6 month ZS call spread rather than stock; the thesis is upside from estimate revisions, not a straight-line breakout, so defined-risk leverage is preferable.
• Do not chase the move if the next data point is only analyst target inflation; wait for billings/cRPO confirmation in the next quarter. A miss there would likely unwind the entire multiple expansion.